Navigation Links
Sunesis Reports Financial Results for the Second Quarter 2009
Date:7/29/2009

r filings with the Securities and Exchange Commission. Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

    Investor Contact:                   Media Contact:
    Sunesis Pharmaceuticals, Inc.       Sunesis Pharmaceuticals, Inc.
    Eric Bjerkholt                      Dan Weinseimer
    650-266-3717                        650-266-3739

                       SUNESIS PHARMACEUTICALS, INC.
                   CONDENSED CONSOLIDATED BALANCE SHEETS

                                               June 30,     December 31,
                                                 2009          2008
                                                 ----          ----
    ASSETS                                    (Unaudited)    (Note 1)
    Current assets:
        Cash and cash equivalents             $6,842,425    $6,296,942
        Marketable securities                    506,619     4,321,844
        Accounts receivable                    1,500,000             -
        Prepaids and other
         current assets                          404,106       934,429
                                                 -------       -------
    Total current assets                       9,253,150    11,553,215
    Property and equipment, net                  407,725       612,241
    Assets held-for-sale                          23,653       470,547
    Deposits and other assets                    101,275       147,826
                                                 -------       -------
    Total assets                              $9,785,803   $12,783,829
                                              ==========   ===========

    
'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Sunesis to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Richardson, Texas (PRWEB) October 20, 2014 ... today announced that a team from Iowa State University ... * design contest. Using a Convey HC-2ex, the team’s ... than 14 times faster than the second place finisher. ... academic world embarked upon the month long challenge, using ...
(Date:10/20/2014)... , Oct. 20, 2014 PureTech , ... tackling big healthcare problems, announced today the closing ... with participation from Invesco Perpetual, a $120 Billion ... to drive PureTech,s existing pipeline forward and to ... has the scientific creativity to really go for ...
(Date:10/19/2014)... OCTOBER 20-22, 2014: The 9th ... will take place at the Congress Center ... is now available at http://www.abim.ch . ... organizations from all over the globe will ... latest products and developments on the world ...
(Date:10/19/2014)... The report "Chocolate, Cocoa Beans, Lecithin, Sugar and ... and Forecast (2011 - 2016)," analyzes the chocolate ... the major market drivers, restraints, and opportunities for the ... The global chocolate market is expected to grow from ... an estimated CAGR of 2.7% from 2011 to 2016. ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4
... ARCA biopharma, Inc.,announced today that the U.S. ... New Drug Application (NDA) for the company,s ... unique,beta-blocker and mild vasodilator developed for the ... the FDA, bucindolol could become the first,genetically ...
... HOUSTON, Sept. 22, 2008 -- Chemists at Rice University ... nanorods -- tiny, wand-like nanoparticles that are being studied ... as diagnosing disease and improving electronic viewscreens. , "The ... synthetic methods is only about 20 percent," said lead ...
... SAN DIEGO, Sept. 22 Neurocrine Biosciences,Inc. (Nasdaq: ... and Chief,Executive Officer of Neurocrine Biosciences will be presenting ... Hyatt in New York., The live presentation takes ... (ET) /7:00 a.m. Pacific Time (PT). The presentation will,be ...
Cached Biology Technology:FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma 2FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma 3Purifying nanorods: Big success with tiny cleanup 2Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference 2
(Date:10/15/2014)... virus is spreading rapidly and to an unexpected extent. ... the past and the virus shows a new disease ... before. For this reason, the German National Academy of ... and Engineering, and the Union of the German Academies ... the Ebola epidemic today. , In the statement the ...
(Date:10/15/2014)...   Neurotechnology , a provider of high-precision ... the VeriLook Surveillance 3.0 software development kit ... face identification using live video streams from single ... version not only identifies faces in a crowd, ... they are moving through the video frame. It ...
(Date:10/14/2014)... – Scientists have sequenced the house fly genome for ... might expect from an insect that thrives in pathogen-rich ... Oct. 14 in the journal Genome Biology , ... and of how flies quickly adapt to resist insecticides, ... house flies (Musca domestica) carry and transmit more than ...
Breaking Biology News(10 mins):Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3House fly genome reveals expanded immune system 2
... Prostate cancer treatments that target the hormone androgen and its ... a new study. Researchers have found that when two genes ... for the hormone androgen, preventing prostate cells from developing normally. ... Cancer Center, suggests that the gene fusion not the ...
... HOLE, MAMitchell Sogin of the Marine Biological Laboratory (MBL) has ... Torrent of Guilford, Conn., and San Francisco. As ... sequencer, a DNA sequencing system that directly translates chemical signals ... a semiconductor chip. The result is a sequencing system that ...
... Specific dioxins derived from the antibacterial agent triclosan, used ... consumer products, account for an increasing proportion of total ... Minnesota research. The study appears online in the ... and Technology . The researchers, from the university,s ...
Cached Biology News:Gene fusions may be the 'smoking gun' in prostate cancer development, U-M study finds 2MBL scientist awarded next-generation DNA sequencer to monitor water quality 2U of Minn. study finds rising levels of dioxins from common soap ingredient in Mississippi River 2
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
... Receptor-gamma (PPAR) is a member of ... transcription factors that heterodimerize with retinoic ... in the regulation of glucose and ... class of anti-diabetic agents called thiazolidinediones ...
... Urine protein analysis can be used for ... to diagnose and/or monitor renal and other diseases. ... collected non-invasively in large amounts, it provides an ... source of disease biomarkers. The ProteoSpin Urine ...
... The ImageXpress 5000A automated cellular imaging and ... software system designed specifically for rapid acquisition ... throughput cell-based screening. ImageXpress is fast. ... resolution (1280 x 1024 pixels), with two ...
Biology Products: